Factors influencing the benefit of adjunctive devices during percutaneous coronary intervention in ST-segment

Related Experiment Video

Updated: Jun 26, 2026

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

Amit P Amin1, Manju R Mamtani, Hemant Kulkarni

  • 1Lata Medical Research Foundation, Nagpur, India.

Journal of Interventional Cardiology
|January 15, 2009
PubMed

Insights

Routine use of adjunctive devices in ST-segment elevation myocardial infarction (STEMI) is not recommended. Thrombectomy devices show benefit, and factors like gender and glycoprotein IIb/IIIa inhibitors may influence outcomes.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Clinical Trials

Background:

  • The efficacy of adjunctive devices during percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) remains debated.
  • Patient characteristics influencing the benefits of these devices are not well-defined.

Purpose of the Study:

  • To systematically review the therapeutic benefits of adjunctive devices in STEMI treatment.
  • To identify patient-specific factors that modulate treatment outcomes.

Main Methods:

  • Conducted meta-analyses of randomized controlled trials (RCTs) comparing adjunctive devices with standard PCI.
  • Assessed reperfusion outcomes including myocardial blush grade (MBG), ST-segment resolution (STR), and Thrombolysis In Myocardial Infarction (TIMI) flow.
  • Performed meta-regressions to analyze trial characteristics and their impact on heterogeneity and clinical endpoints like MACE.

Main Results:

  • Meta-analyses included 23 RCTs with 5,728 patients, showing 32-35% benefit for reperfusion outcomes.
  • Thrombectomy devices demonstrated greater efficacy than distal protection devices.
  • Gender, glycoprotein (GP) IIb/IIIa inhibitor use, and baseline TIMI flow grade significantly predicted improved reperfusion.

Conclusions:

  • Routine use of adjunctive devices in STEMI is not supported by current evidence.
  • Thrombus burden, GP IIb/IIIa inhibitor treatment, and gender are potential modifiers of reperfusion benefit.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...